tbuckley/cabot-search huggingface dataset:
COMMUNITY HEALTH WEEK
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P59 Subanalyses of the Telaprevir lead-in arm in the realize study: response at week 4 is not a substitute for prior null response categorisation
Authors: G. Foster
Journal: Gut (2011)

<h3>Introduction</h3> On treatment, a poor therapeutic response to peginterferon (P)/ribavirin (R) is defined as a &lt;1 log10 decline in viral load at week 4. Null response (NR) to a current or prior course of PR is defined as a &lt;2 log10 decline in HCV RNA at week 12. The FDA adopted the week 12 NR definition in its recent draft guidance. The REALIZE study uniquely enrolled classically defined prior NR, partial responders and relapsers, and included an arm with a PR lead-in (L-I) phase. This design allows a comparison of on treatment response after 4 weeks of PR with prior response categories, including a comparison of ‘null response’, as well as the relationship between &lt; or −1 log10 RNA decline and SVR in response to T/PR treatment. <h3>Method</h3> Patients in the lead-in arm (N=240) received 4 weeks of PR followed by telaprevir (T) 750 mg 8 hourly for 12 weeks combined with PR followed by 32 weeks of PR alone. Control patients (N=121) received 48 weeks of PR. All patients received pegylated interferon alfa-2a. <h3>Results</h3> 10% of prior relapsers and 31–40% of partial responders (shaded cells), had &lt;1 log10 decline in HCV RNA at week 4 in the control and L-I arm, respectively. SVR rates in the T L-I arm among prior relapsers and partial responders were higher (62% and 56%, respectively; combined SVR=58%) than in prior week 12 NR who experienced &lt;1 log10 decline in HCV RNA (15%). Although patients with −1 log10 response at end of the L-I phase had the highest SVR rates, SVR in T/PR patients with &lt;1 log10 was considerably higher (62±15%) than control (0%). <h3>Conclusion</h3> Poor interferon responders on treatment (&lt;1 log10 decline in HCV RNA at week 4) are not the same as prior PR NR (&lt;2 log10 at week 12). SVR rates in T/PR patients were higher than control irrespective of their response (&lt; or −1 log10) at the end of the L-I phase. Safety findings in the T arm were similar irrespective of week 4 response.
Hepatic iron in hereditary hemochromatosis (HHC): A multicenter United States study , EL Krawitt, T Trainer, K Susskind, D Pratt, TA Knox, MM Kaplan, R Rubin, JR Saltzman, HL Bonkovsky, ND Grace. University of Washington, University of Vermont, University of Massachusetts, and Tufts Univesity
Journal: Hepatology (1995)
Shared Body
Authors: Anne Dohrenwend
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Nervous System and its Constituent Neurons.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2998: Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy
Authors: Andrew Sulaiman, Sara El-Sahli, Sarah McGarry, Lisheng Wang, Suresh Gadde
Journal: Cancer Research (2019)

Abstract Triple negative breast cancer (TNBC) accounts disproportionally for the majority of breast cancer related deaths throughout the world. This is largely attributed to lack of a specific therapy capable of targeting both bulk tumor mass and cancer stem cells (CSC) as well as appropriate tumor animal models to accurately evaluate treatment efficacy for the clinical translation. Thus, development of effective and clinically translatable targeted therapies for TNBC is an unmet medical need. In this report, we developed a hybrid nanoparticles-based co-delivery platform containing both paclitaxel and verteporfin (PV-NPs) to target TNBC patient-derived xenograft (PDX) tumor and CSCs. MRI and IVIS imaging were performed on mice containing PDX tumors to assess tumor vascularity and selective accumulation of NPs. NF-kB, Wnt and YAP activities were measured by reporter assays. Mice bearing TNBC PDX tumor were treated with PV-NPs and controls; and tumors progression and CSC subpopulations were analyzed. Our MRI imaging studies indicated high vascularization of PDX tumors. IVIS imaging showed selective accumulation of NPs in PDX tumors. In comparison to control NPs and free-drug combination, PV-NPs significantly retarded tumor growth of TNBC PDX. PV-NPs simultaneously repressed NF-kB, Wnt and YAP that have been shown to be crucial for cancer growth, CSC development and tumorigenesis. In conclusion, NPs containing two clinically used drugs concurrently inhibited NF-kB, Wnt and YAP pathways and exhibited synergic effects on killing TNBC bulk tumor and CSCs. This combination nanotherapy evaluated with a PDX model may lead to an effective treatment of TNBC patients. Note: This abstract was not presented at the meeting. Citation Format: Andrew Sulaiman, Sara El-Sahli, Sarah McGarry, Lisheng Wang, Suresh Gadde. Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2998.
Trace Pain
Authors: Mark LaRue
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: A. BEDI
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Get access Progress in clinical and Biological Research, Volume 352, The Biology of Hematopoiesis . Nicholos Dainiak , Eugene P. Cronkite , Ronald MCCaffrey , Richard K. Shadduck , eds. New York : Wiley & Liss , 1990 , 554 pp. $125. ATUL BEDI ATUL BEDI Experimental Hematopoiesis, Johns Hopkins Oncology Center600 N.Wolfe st., Rm.2-127, Baltimore, MD 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 12, 19 June 1991, Pages 876–877, https://doi.org/10.1093/jnci/83.12.876-a Published: 19 June 1991
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment
Authors: Elliott M. Antman, Jeroen Bax, Richard A. Chazal, Mark A. Creager, Gerasimos Filippatos, Jonathan L. Halperin, Steven Houser, JoAnn Lindenfeld, Fausto J. Pinto, Panos Vardas, Mary Norine Walsh, Kim A. Williams, Jose L. Zamorano
Journal: Journal of the American College of Cardiology (2016)
Radioactive patients.
Authors: P. J. Mountford, A. J. Coakley
Journal: BMJ (1989)

but reduced the proportion of patients with prolonged post-herpetic neuralgia.22Many other reports have dealt with various treatments, but these all need evaluating by controlled studies.' Clinical experience suggests that systemic analgesics, either non-steroidal anti-inflammatory drugs or an opioid drug, may moderate the acute pain in herpes zoster, but evaluations of their efficacy have not been reported.][24][25] Baclofen may have a therapeutic role in controlling the pain,21 27 and an epidural injection of steroids is efficacious to the extent that it may be the best treatment for chronic intractable neuralgia when steroids are not contraindicated.28Acupuncture29 and transcutaneous stimulation303' are other possibly effective adjuvant treatments.Finally, preliminary results suggest that topical capsicum, a neuropeptide active agent, may have an important therapeutic role in post-herpetic neuralgia.3233
KIT Blockade Is Sufficient to Sustain Donor Hematopoietic Stem Cell Engraftment in Fanconi Anemia Mice
Authors: Shanmuganathan Chandrakasan, Rajeswari Jayavaradhan, Ernst John, Archana Shrestha, Phillip Dexheimer, Michael B. Jordan, Qishen Pang, Bruce J. Aronow, Punam Malik
Journal: Blood (2015)
The PSRC1 rs599839 A &gt; G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients
Authors: Marica Meroni, Miriam Longo, Raffaela Rametta, Anna Alisi, Luca Miele, Luca Valenti, Anna Ludovica Fracanzani, Paola Dongiovanni
Journal: Journal of Hepatology (2020)
Abstract 5893: Biventricular Versus Right Ventricular Delivered Anti-Tachicardia Pacing for the Termination Of Ventricular Tachyarrhythmias in Heart Failure Patients Receiving a Biventricular ICD: Results from the ADVANCE CRT-D Trial
Authors: Maurizio Gasparini, Frédéric Anselme, Jacques Clémenty, Massimo Santini, José Martinez-Ferrer, Marc Mainardi, Tiziana De Santo, Giuseppe Ligorio, Joerg O Schwab
Journal: Circulation (2008)

Aim: To investigate the efficacy and safety of anti-tachycardia pacing (ATP) simultaneously delivered from right and left ventricles (BIV) vs conventional right ventricular (RV) delivery in heart failure (HF) patients treated with a biventricular ICD (CRT-D). Methods : Multicenter, prospective, randomized, controlled trial of pts implanted with a Medtronic CRT-D device. Anti-tachycardia detections were programmed: VF detection set at NID 18/24 for ≥250 bpm; FVT (via VF) with NID 18/24 between 188–250 bpm; VT detected when 20 consecutive RR intervals ≥143 bpm. Randomization was 1:1 to either BiV or RV ATP (single burst 8 pulse, 88% coupling interval ). Pts were followed for 12 months. Stored EGM, used to classify all spontaneous episodes, as well as all adverse events (including death) were adjudicated by an independent committee adjusting for pts with multiple episodes. The primary end-point (PEP) compared the efficacy of first BiV vs RV to terminate any ventricular tachyarrhythmias (VTs). The secondary composite end-point (SEP) compared adverse events (accelerations+ syncope/pre-syncope) to assess safety. Results : In total, 526 patients were enrolled and randomized (BiV = 260, RV = 266). There were no baseline differences between groups. In total, 1077 detections in 178 patients were recorded: 634 were true VTs in 119 patients (69 VF [11%] in 18 pts, 202 FVT [32%] in 49 pts, and 363 VT [57%] in 92 pts). PEP: Efficacy of first ATP was comparable between BiV (65%) and RV (68%) (p=0.58). In VT zone, RV was better (62% vs 71%., p=0.24), while in FVT zone BIV proved better (71% vs. 61%, p=0.33). RV ATP was significantly less effective in ischemic (I) pts (81% vs 59%, p=0.005). SEP: BIV ATP was ineffective 20 times and 3 accelerations occurred, whereas RV ATP failed 41 times and 14 accelerations occurred (p=0.12). Syncope/pre-syncope events never occurred for BiV ATP, while 4 times (3%) in RV ATP(p=0.3). No difference in mortality was observed. Conclusion : This trial demonstrated that ATP is also effective in CRT-D recipients. No significant differences in overall ATP efficacy were found between BIV and RV, but RV was significantly less effective in I patients; BIV was effective across different etiologies and showed a trend for superior safety profile.
CHANGES IN STATE MEDICAL PERIODICALS
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk Stratification for Coronary Bypass Surgery in Patients With Left Ventricular Dysfunction
Authors: Michael Argenziano, Henry M. Spotnitz, William Whang, J. T. Bigger, Michael Parides, Eric A. Rose
Journal: Circulation (1999)

Background —Preoperative characteristics may influence morbidity and mortality in patients undergoing coronary artery bypass grafting (CABG). The CABG Patch Trial was designed to assess the impact of prophylactic insertion of an implantable cardioverter-defibrillator in patients undergoing high-risk CABG. This database was used to investigate the influence of symptomatic congestive heart failure (CHF) and angina on morbidity and mortality in CABG patients with ventricular dysfunction. Methods and Results —Data were analyzed for 900 randomized patients with an ejection fraction ≤35% and an abnormal signal-averaged ECG. Single-variable and stepwise multiple logistic regression analyses were used for mortality and length-of-stay (LOS) data. Severity of CHF and angina was graded by the New York Heart Association (NYHA) and Canadian Cardiovascular Society (CCS) classifications, respectively. Perioperative mortality was 3.5% in 454 patients without clinical signs of heart failure versus 7.7% in 443 patients with NYHA class I to IV heart failure ( P =0.018). By multiple logistic regression analysis, mortality was significantly higher in patients with preoperative symptomatic (NYHA class I to IV) heart failure (odds ratio, 2.4; P =0.01) or reoperation (odds ratio, 3.8; P &lt;0.0001). Mortality was not significantly influenced by age, sex, the presence or severity of angina, hypertension, left main coronary artery disease, pulmonary disease, or severity of CHF (although LOS was increased 0.7 days per NYHA class). Patients with a history of stroke had a higher rate of perioperative stroke (16.4% versus 3.6%, P =0.001) and an increased LOS (by 3.5 days). Conclusions —Symptomatic heart failure and reoperation are predictors of increased operative mortality in patients with ventricular dysfunction and a positive signal-averaged ECG. Conversely, patients without heart failure symptoms may undergo CABG with relatively low mortality despite low ejection fraction. LOS is prolonged significantly by advanced age, history of stroke, and the presence and severity of heart failure.
Psychophysiologic Aspects of Severe Behavior Disorders
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Wording
Authors: Harold Pincus, Terri Tanielian, Deborah Zarin, Steven Marcus, Joel Alpert, Suzanne Steinbach
Journal: JAMA (1998)

Does This Infant Have Pneumonia? The Value of Chest PercussionTo the Editor.-DrsMargolis and Gadomski 1 state, "Textbooks do not recommend percussion of the chest in infants because it is difficult to get infants to cooperate with this maneuver." 1However, we believe that chest percussion is helpful in the diagnosis of pneumonia, and we regularly demonstrate to colleagues, students, and residents the value of percussion in examining an infant's chest. 2 Chest percussion requires no greater cooperation from the patient than does auscultation.Rather than discourage the use of percussion, pediatric textbooks specifically describe the utility and limitations of this method in infantile pneumonia, emphasizing that both auscultation and percussion may fail to elicit abnormalities in infants with pneumonia 3,4 and that when localized dullness is detected in infants, pleural effusion or empyema should be suspected. 4Textbook authors appear to encourage chest percussion in the examination of older children.Finally, while the article's title refers to infants, the text frequently refers to children.The terms infants and children and data obtained from their assessment should not be used interchangeably.We suggest that omission of chest auscultation from the physical examination will result in the loss of even more than the examiner's skill to detect pneumonia, namely, the "gratification for clinician as well as for patient in the laying-on of hands." 5 Clinicians should reconsider before abandoning a technique such as percussion, which provides a time-honored method for initiating the healing process.While respecting old methods, we also appreciate new technology and question the omission of pulse oximetry from the discussion.Pulse oximetry has been shown to identify pediatric patients with acute lower respiratory tract infection who require treatment, certainly those who require supplemental oxygen. 6The objective nature of pulse oximetry makes it particularly useful in assessing infants with respiratory distress, precisely because of the limited interobserver agreement with chest percussion and auscultation.A thoughtful synthesis of old and new assessment methods will provide the greatest yield for both clinician and pediatric patients.
Overall survival in patients with lung cancer using a web-application-guided follow-up compared to standard modalities: Results of phase III randomized trial.
Authors: Fabrice Denis, Claire Lethrosne, Nicolas Pourel, Olivier Molinier, Yoann Pointreau, Julien Domont, Hugues Pierre Bourgeois, Helene Senellart, Pierre Tremolieres, Thibaut Lizee, Jaafar Bennouna, Thierry Urban, Claude El Kouri, Alexandre Charron, Anne-Lise Septans, Magali Balavoine, Cyrielle Rolley, Sebastien Landry, Philippe Solal-Celigny, Christophe Letellier
Journal: Journal of Clinical Oncology (2016)

LBA9006 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 6, 2016, and in the Annual Meeting Proceedings online supplement to the June 20, 2016, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis
Authors: Marcus Mücke, Victoria Therese Mücke, Christiana Graf, Katharina Maria Schwarzkopf, Philip Ferstl, Javier Fernandez, Stefan Zeuzem, Jonel Trebicka, Christian Lange, Eva Herrmann
Journal: Journal of Hepatology (2020)